CAMBRIDGE, Mass., Nov. 19, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the J.P. Morgan SMid Cap Conference on Thursday, November 29, 2012 at 8:45 a.m. (ET) at the J.P. Morgan Conference Center in New York, New York.
A live webcast of Merrimack's presentation can be accessed by visiting the investor relations section of the company's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Investor & Media Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, firstname.lastname@example.orgSource:Merrimack Pharmaceuticals